FC
CRSP icon

Fairscale Capital’s CRISPR Therapeutics CRSP Stock Holding History

Fairscale Capital’s Portfolio CRSP Stock Details CRSP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$3.22K Hold
59
– – ﹤0.01% 368
2026
Q1 		$2.81K Hold
59
– – ﹤0.01% 369
2025
Q4 		$3.09K Sell
59
-55
-48% -$3.29K ﹤0.01% 356
2025
Q3 		$7.39K Hold
114
– – 0.01% 343
2025
Q2 		$6.41K Sell
114
-3
-3% -$116 ﹤0.01% 345
2025
Q1 		$3.98K Hold
117
– – ﹤0.01% 279
2024
Q4 		$4.61K Hold
117
– – ﹤0.01% 273
2024
Q3 		$5.5K Sell
117
-91
-44% -$4.62K ﹤0.01% 269
2024
Q2 		$13.1K Buy
+208
New +$12K 0.01% 247

Other funds holding CRSP

AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
OAG
Orbis Allan Gray Hamilton, Bermuda $29.1B AUM 60.8% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
GP
GSK plc London $602M AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
SOCM
SR One Capital Management Wayne, Pennsylvania $1.04B AUM 262.99% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Fairscale Capital's CRSP Position: Q2 2026 in Review

Fairscale Capital held its CRISPR Therapeutics (CRSP) position steady in Q2 2026 at 59 shares worth $3.22K. The position accounts for ﹤0.01% of the portfolio, ranked #368.

Fairscale Capital first reported a position in CRSP in Q2 2024 and has held it in 9 quarters since. The position peaked at $13.1K in Q2 2024. 523 funds tracked by Wall St. Rank hold CRSP as of Q2 2026.

  • Fairscale Capital held 59 shares of CRISPR Therapeutics worth $3.22K as of Q2 2026.
  • Fairscale Capital left its CRISPR Therapeutics share count unchanged in Q2 2026.
  • CRISPR Therapeutics made up ﹤0.01% of Fairscale Capital's portfolio in Q2 2026, its #368 holding.
  • Fairscale Capital first reported a position in CRISPR Therapeutics in Q2 2024 and has held it in 9 quarters since.
  • Fairscale Capital's CRISPR Therapeutics position peaked at $13.1K in Q2 2024.
  • 523 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q2 2026.

Based on Fairscale Capital's 13F filing for Q2 2026, filed 7 Aug 2026.